Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.

Product Launch and Stocking - Scilex is launching its third commercial product, GLOPERBA®, which is the first and only liquid oral formulation of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults [1][7] - Stocking of GLOPERBA® is underway in all wholesalers with which Scilex has stocking arrangements throughout the U S, and completion is expected by June 12, 2024 [1][7] - Patients will have access to a co-pay savings card for GLOPERBA® [1] Product Pipeline - Scilex has three product candidates: SP-102 (SEMDEXA™), a novel viscous gel formulation of dexamethasone sodium phosphate for epidural injections to treat sciatica, which has completed Phase 3 trials and received FDA Fast Track status in 2017 [2] - SP-103, a next-generation triple-strength formulation of ZTlido for chronic neck pain, has completed Phase 2 trials for low back pain and received FDA Fast Track status [2] - SP-104, a low-dose delayed-release naltrexone hydrochloride capsule for fibromyalgia, completed Phase 1 trials in Q2 2022 [2] Company Overview - Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [16] - The company targets indications with high unmet needs and large market opportunities, aiming to improve patient outcomes with non-opioid therapies [16] - Scilex's commercial products include ZTlido® for neuropathic pain, ELYXYB® for migraine treatment, and GLOPERBA® for gout flare prophylaxis [16] Trademarks and Intellectual Property - GLOPERBA® is the subject of an exclusive, transferable license to Scilex Holding Company for the use of the registered trademark [5] - SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc, a wholly-owned subsidiary of Scilex Holding Company, with a proprietary name review by the FDA planned [10] - ZTlido® and ELYXYB® are registered trademarks owned by Scilex Pharmaceuticals Inc and Scilex Holding Company, respectively [17][18]